Healthcare · Pharmaceuticals & Biotechnology
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Mumbai. Founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, it is listed on the Bombay Stock Exchange and the National Stock Exchange of India. The company produces and distributes medicines in more than 80 countries, with operations concentrated in India, North America, Europe, and emerging markets. As of March 2026, it employed approximately 17,000 people. Its name derives from Saldanha's sons, Glenn and Mark.
Source: Wikipedia
| Fiscal year | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Total income (before exceptional items) | 9,212† | 9,583† | 9,059† | 9,207† | 8,756† |
| Net profit | -201 | 1,610 | 5,167 | 1,209 | 1,998† |
₹ Crore. † Summed from the four quarterly filings of that fiscal year.
Current board roster from exchange filings. Director remuneration is not in our data, so it isn't shown.
| Name | Designation | Term end |
|---|---|---|
| ANURAG MANTRI | Executive Director | June 30, 2026 |
| CHERYLANN MARIA PINTO | Executive Director | June 30, 2026 |
| GLENN MARIO SALDANHA | Executive Director | June 30, 2026 |
| DIPANKAR BHATTACHARJEE | Independent Director | June 30, 2026 |
| PATRICIA ANDREWS | Independent Director | June 30, 2026 |
| PRADEEP KUMAR SINHA | Independent Director | June 30, 2026 |
| SAIRA RAMASASTRY | Independent Director | June 30, 2026 |
| VIJAYALAKSHMI RAJARAM IYER | Independent Director | June 30, 2026 |
| BLANCHE ELIZABETH SALDANHA | Non-Executive Director | June 30, 2026 |
Key management names, their remuneration, subsidiaries and brand listings are not in the exchange filings we ingest yet, so they are not shown here rather than estimated.
